Amgen News - LARVOL Sigma

«1 2...79 80 81 82 838485 86 87 88 89...858 859 »

|||||||||| Krystexxa (pegloticase) / Amgen, Rituxan (rituximab) / Roche
Resolution of Severe Tophi with Recombinant Uricase in A Kidney Transplant Recipient () - Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_955;
Recombinant uricase shows effectiveness in KTR with severe gout with significant tophi. Further clinical trials are warranted to evaluate the efficacy and safety of recombinant uricase in this high-risk population.

|||||||||| Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
A refractory case of rapidly progressive glomerulonephritis due to microscopic polyangiitis () - Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_546;
MPA is a major cause of AAV and portends a poor prognosis without aggressive immunosuppressive therapy, including glucocorticoids and either rituximab or cyclophosphamide for severe cases. For many patients, especially those showing poor response to initial therapy, avacopan may provide a safer and potentially more efficacious treatment for AAV.

|||||||||| cinacalcet HCl / Generic mfg.
Nephrogenic Diabetes Insipidus secondary to Hypercalcemia of Malignancy responsive to Cinacalcet () - Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_541;
Ionized calcium remained the same despite Zometa, calcitonin, denosumab, and aggressive IVF with NS...Desmopressin was then initiated but did not sufficiently concentrate the urine... This case exhibits the potential use of cinacalcet for the treatment of nephrogenic DI secondary to hypercalcemia of malignancy.

|||||||||| Libtayo (cemiplimab-rwlc) / Regeneron
A case of cemiplimab-induced hypercalcemia in metastatic squamous cell carcinoma () - Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_504;
It is important to recognize ICI-associated hypercalcemia. Ongoing research is imperative to understand the underlying mechanisms and the optimal approaches to management.

|||||||||| Enbrel (etanercept) / Pfizer, Amgen
Electrical stimulation of the arterial splenic nerve has durable therapeutic efficacy on murine collagen-induced arthritis. (Room W181) - Mar 22, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_322;
Importantly, the therapeutic efficacy of SNS was enhanced when combined with etanercept treatment. The results of this study suggest that SNS may have potent therapeutic anti-arthritogenic effects.

|||||||||| Ibrance (palbociclib) / Pfizer
Clinical, Journal: A rare case of Takotsubo cardiomyopathy. (Pubmed Central) - Mar 22, 2024
The results of this study suggest that SNS may have potent therapeutic anti-arthritogenic effects. Pharmacovigilance and experimental studies are warranted to confirm any causative relationship and to explore the underlying pathophysiology, respectively.

|||||||||| Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Siliq (brodalumab) / Bausch Health
Journal: Deep analysis of skin molecular heterogeneities and their significance on the precise treatment of patients with psoriasis. (Pubmed Central) - Mar 22, 2024
inhibitors (etanercept) and interleukin-17A receptor inhibitors (brodalumab) but not methotrexate and interleukin-12/23 inhibitors. Psoriasis patients can be assorted into three subtypes with different molecular and cellular characteristics based on the heterogeneity of the skin's immune cells and the stroma, determining the clinical responses of conventional therapies.

|||||||||| Ibrance (palbociclib) / Pfizer
Review, Journal, Real-world evidence, Real-world, Metastases: Prolonging the lives of African-Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study. (Pubmed Central) - Mar 22, 2024
P=N/A
These results support the use of palbociclib with an AI as a first treatment for African-Americans with HR+/HER2- MBC. Clinical Trial Registration: NCT05361655 (ClinicalTrials.gov).

||||||||||  brimarefenib (BGB-3245) / MapKure, SpringWorks Therap
Enrollment open:  BGB-3245-EGFR-001: A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers (clinicaltrials.gov) -  Mar 22, 2024
P1, N=64, Recruiting,  Sponsor: MapKure, LLC
Clinical Trial Registration: NCT05361655 (ClinicalTrials.gov). Not yet recruiting --> Recruiting

||||||||||  AMG 562 / Amgen
Trial termination:  Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma (clinicaltrials.gov) -  Mar 22, 2024
P1, N=10, Terminated,  Sponsor: Amgen
Not yet recruiting --> Recruiting Completed --> Terminated; Amgen decided to discontinue study because of a business decision and not because of safety reasons

||||||||||  bemarituzumab (AMG 552) / Amgen
Trial completion date, Trial primary completion date:  FORTITUDE-103: A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. (clinicaltrials.gov) -  Mar 22, 2024
P1, N=80, Recruiting,  Sponsor: Amgen
Completed --> Terminated; Amgen decided to discontinue study because of a business decision and not because of safety reasons Trial completion date: Sep 2027 --> Apr 2028 | Trial primary completion date: May 2026 --> Nov 2026

||||||||||  Lumakras (sotorasib) / Amgen
Trial completion date, Metastases:  AMG 510 Ethnic Sensitivity Study (CodeBreaK 105). (clinicaltrials.gov) -  Mar 22, 2024
P1, N=12, Active, not recruiting,  Sponsor: Amgen
Trial completion date: Sep 2027 --> Apr 2028 | Trial primary completion date: May 2026 --> Nov 2026 Trial completion date: Mar 2023 --> Jul 2024

||||||||||  Krystexxa (pegloticase) / Amgen
Enrollment open, Head-to-Head:  A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout (clinicaltrials.gov) -  Mar 22, 2024
P4, N=240, Recruiting,  Sponsor: Horizon Therapeutics Ireland DAC
Trial completion date: Mar 2023 --> Jul 2024 Not yet recruiting --> Recruiting

||||||||||  Kepivance (palifermin) / SOBI, Amgen, Neupogen (filgrastim) / Kyowa Kirin, Amgen
New P1/2 trial:  Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (clinicaltrials.gov) -  Mar 22, 2024
P1/2, N=10, Not yet recruiting,  Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

|||||||||| Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche
Journal: Evaluating a targeted Palbociclib-Trastuzumab loaded smart niosome platform for treating HER2 positive breast cancer cells. (Pubmed Central) - Mar 22, 2024
Fluorescence imaging further validated the internalization of particles into cells. In conclusion, Trz-Pal-pHSNs emerge as a promising platform for personalized medicine in the treatment of HER2-positive breast cancer.

||||||||||  Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date, Metastases:  PATHWAY: PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY (clinicaltrials.gov) -  Mar 22, 2024
P3, N=180, Active, not recruiting,  Sponsor: National Cancer Center, Japan
In conclusion, Trz-Pal-pHSNs emerge as a promising platform for personalized medicine in the treatment of HER2-positive breast cancer. Trial completion date: Apr 2025 --> Sep 2025 | Trial primary completion date: Apr 2025 --> Sep 2025

||||||||||  navtemadlin (KRT-232) / Kartos Therap
Phase classification, Trial completion date, Trial termination, Combination therapy:  An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov) -  Mar 22, 2024
P1/2, N=70, Terminated,  Sponsor: Kartos Therapeutics, Inc.
Trial completion date: Apr 2025 --> Sep 2025 | Trial primary completion date: Apr 2025 --> Sep 2025 Phase classification: P1b/2 --> P1/2 | Trial completion date: Jul 2024 --> Sep 2023 | Active, not recruiting --> Terminated; In September 2023, the study was terminated because of a Sponsor decision, unrelated to safety concerns.

||||||||||  navtemadlin (KRT-232) / Kartos Therap
Phase classification, Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Metastases:  Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) -  Mar 22, 2024
P1/2, N=0, Withdrawn,  Sponsor: Kartos Therapeutics, Inc.
Phase classification: P1b/2 --> P1/2 | Trial completion date: Jul 2024 --> Sep 2023 | Active, not recruiting --> Terminated; In September 2023, the study was terminated because of a Sponsor decision, unrelated to safety concerns. Phase classification: P1b/2 --> P1/2 | N=92 --> 0 | Trial completion date: Dec 2027 --> Jun 2027 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2025 --> Jun 2025

|||||||||| digoxin / Generic mfg., ivabradine / Generic mfg.
Journal: Impact of heart rate changes during hospitalization on outcome in heart failure with preserved ejection fraction. (Pubmed Central) - Mar 22, 2024
In hospitalized HFpEF patients, excessive HR dropping during hospitalization is associated with an increased risk of CV death or HF rehospitalization. These findings highlight the importance of HR monitoring and avoiding excessively slowing down HR in hospitalized HFpEF patients to reduce the risk of CV events.

|||||||||| ivabradine / Generic mfg.
Journal: Effects of Ivabradine on Myocardial Perfusion in Chronic Angina: A Prospective, Preliminary, Open-Label, Single-Arm Study. (Pubmed Central) - Mar 22, 2024
Ivabradine added to beta blockers was associated with a reduction in detectable myocardial ischemia by MPS in patients with CA. Infographic available for this article.

||||||||||  blinatumomab subcutaneous / Amgen
Trial completion date, Trial primary completion date:  A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients (clinicaltrials.gov) -  Mar 22, 2024
P1/2, N=125, Recruiting,  Sponsor: Amgen
Infographic available for this article. Trial completion date: Mar 2029 --> Sep 2028 | Trial primary completion date: Jun 2027 --> Nov 2026

||||||||||  H3B-6545 / Eisai
Phase classification, Combination therapy, Metastases:  H3B-6545-G000-102: A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer (clinicaltrials.gov) -  Mar 22, 2024
P1, N=31, Active, not recruiting,  Sponsor: Eisai Inc.
Trial completion date: Mar 2029 --> Sep 2028 | Trial primary completion date: Jun 2027 --> Nov 2026 Phase classification: P1b --> P1

||||||||||  Liporaxel (paclitaxel oral) / Dae Hwa, HaiHe Biopharma, Stivarga (regorafenib) / Bayer
New P2 trial:  GIST Oral Paclitaxel(Liporaxel) (clinicaltrials.gov) -  Mar 22, 2024
P2, N=28, Not yet recruiting,  Sponsor: Asan Medical Center

|||||||||| Lumakras (sotorasib) / Amgen
Preclinical, Journal: A pair of primary colorectal cancer-derived and corresponding synchronous liver metastasis-derived organoid cell lines. (Pubmed Central) - Mar 22, 2024
The corresponding adherent cultured CWH22-2D/CLM22-2D cells were established and compared with commonly used CRC cell lines from the ATCC. Both organoids are publicly available to all researchers and will be useful tools for specific human CRC/CLM studies both in vitro and in vivo.

|||||||||| Quinsair (levofloxacin inhalational) / Chiesi, Amgen
A retrospective review of fluoroquinolone associated tendinopathy among cystic fibrosis patients in a national cystic fibrosis centre (Exhibition and Poster Area) - Mar 22, 2024 - Abstract #ECFS2024ECFS_690;
Both organoids are publicly available to all researchers and will be useful tools for specific human CRC/CLM studies both in vitro and in vivo. The aim was to determine if they had been prescribed ciprofloxacin and/ or Quinsar

|||||||||| Trikafta (elexacaftor/tezacaftor/ivacaftor) / Vertex, Quinsair (levofloxacin inhalational) / Chiesi, Amgen
Pulmonary infection caused by Dyella species in cystic fibrosis (Exhibition and Poster Area) - Mar 22, 2024 - Abstract #ECFS2024ECFS_442;
At the age of 10, a culture showed scanty growth of a Gram negative, environmental microorganism that was totally resistant to Colistin and had decreased susceptibility to several other antibiotics...Eradication failed, but the girl received several intravenous treatments (using mainly Meropenem and Tigecycline) followed by long courses of inhaled Levofloxacine and oral Trim/Sulfa...In December 2022, Ivacaftor/Tezacaftor/Elexacaftor became available in Sweden, and was initiated... Dyella species is a rare cause of airway colonization in CF but can lead to clinical deterioration.

|||||||||| Blincyto (blinatumomab) / Astellas, Amgen, GSK 2190914 / GSK
HSS9007: T-cell engaging immunotherapy in early treatment of B-cell acute lymphoblastic leukemia (B-ALL) (Hall N101; Hybrid) - Mar 22, 2024 - Abstract #EHA2024EHA_4;
Dyella species is a rare cause of airway colonization in CF but can lead to clinical deterioration. The third presentation, "Novel approaches in pediatric populations" will be covered by Martin Schrappe (DE) which will be followed by a panel discussion on future perspectives together with Nicola G

||||||||||  ECT204 / Eureka Therap
Trial completion date, Trial primary completion date, Metastases:  ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov) -  Mar 21, 2024
P2, N=24, Recruiting,  Sponsor: Eureka Therapeutics Inc.
The third presentation, "Novel approaches in pediatric populations" will be covered by Martin Schrappe (DE) which will be followed by a panel discussion on future perspectives together with Nicola G Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2026

||||||||||  trebananib (AMG 386) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Metastases:  Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor (clinicaltrials.gov) -  Mar 21, 2024
P1, N=60, Active, not recruiting,  Sponsor: Dana-Farber Cancer Institute
Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2026 Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Feb 2024 --> Feb 2025

||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment open:  The Role of Granulocyte Colony Stimulating Factor in Embryo Transfer Outcomes (clinicaltrials.gov) -  Mar 21, 2024
P4, N=300, Recruiting,  Sponsor: Newlife Fertility Centre
Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Feb 2024 --> Feb 2025 Not yet recruiting --> Recruiting

|||||||||| Ibrance (palbociclib) / Pfizer, Bavencio (avelumab) / EMD Serono
P2 data, Journal, Metastases: PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. (Pubmed Central) - Mar 21, 2024
The addition of palbociclib to fulvestrant did not improve PFS versus fulvestrant alone among patients with hormone receptor-positive/HER2- MBC whose disease had progressed on a previous CDK4/6i plus AI. The increased PFS seen with the addition of avelumab warrants further investigation in this patient population.

||||||||||  Remicade (infliximab) / J&J, Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Trial completion date, Trial primary completion date, Adverse events:  PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma (clinicaltrials.gov) -  Mar 21, 2024
P2, N=36, Recruiting,  Sponsor: Massachusetts General Hospital
The increased PFS seen with the addition of avelumab warrants further investigation in this patient population. Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2023 --> Jun 2025

||||||||||  Prolia (denosumab) / Amgen
Enrollment closed, Head-to-Head:  REDUSE: Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks (clinicaltrials.gov) -  Mar 21, 2024
P3, N=1380, Active, not recruiting,  Sponsor: Swiss Group for Clinical Cancer Research
Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2023 --> Jun 2025 Recruiting --> Active, not recruiting

||||||||||  LTC004 / Leto Laboratories, Stivarga (regorafenib) / Bayer
New P2 trial, Combination therapy, Metastases:  Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC (clinicaltrials.gov) -  Mar 21, 2024
P2, N=20, Not yet recruiting,  Sponsor: Tianjin Medical University Cancer Institute and Hospital

||||||||||  Prolia (denosumab) / Amgen
Trial completion date, Trial primary completion date:  Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations. (clinicaltrials.gov) -  Mar 21, 2024
P=N/A, N=100, Recruiting,  Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Mar 2025

||||||||||  Stivarga (regorafenib) / Bayer
New trial, Real-world evidence, Real-world, Stroma, Metastases:  An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States (clinicaltrials.gov) -  Mar 21, 2024
P=N/A, N=136, Not yet recruiting,  Sponsor: Bayer

|||||||||| Trial completion date: SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors (clinicaltrials.gov) - Mar 21, 2024
P1, N=68, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Mar 2025 Trial completion date: Mar 2025 --> May 2024

||||||||||  Lumakras (sotorasib) / Amgen
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) -  Mar 21, 2024
P1, N=15, Recruiting,  Sponsor: City of Hope Medical Center
Trial completion date: Mar 2025 --> May 2024 Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Mar 2026 | Trial primary completion date: Apr 2025 --> Mar 2026

|||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Observational data, Retrospective data, Journal, Real-world evidence, Real-world: Blood pressure elevation in erenumab-treated patients with migraine: A retrospective real-world experience. (Pubmed Central) - Mar 21, 2024
Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Mar 2026 | Trial primary completion date: Apr 2025 --> Mar 2026 We found that 23.3% of patients initiated on erenumab may have developed worsening BP, suggesting the need for BP monitoring in patients initiated on erenumab.

|||||||||| Clinical, Retrospective data, Review: Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis. (Pubmed Central) - Mar 21, 2024
This risk is higher in MS treatment, and specifically during long-term natalizumab therapy. While this drug is still routinely prescribed in this field, considering the efficacy in reducing MS relapses, in other areas it could play a smaller role, and be gradually replaced by other safer and more recently approved agents.

||||||||||  Ibrance (palbociclib) / Pfizer
Trial primary completion date, Liquid biopsy, Metastases, Biopsy:  ICRG0201: Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies. (clinicaltrials.gov) -  Mar 21, 2024
P2, N=80, Recruiting,  Sponsor: International Cancer Research Group, United Arab Emirates
While this drug is still routinely prescribed in this field, considering the efficacy in reducing MS relapses, in other areas it could play a smaller role, and be gradually replaced by other safer and more recently approved agents. Trial primary completion date: Jan 2024 --> Dec 2024

||||||||||  Tavneos (avacopan) / Amgen
New P3 trial:  Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV. (clinicaltrials.gov) -  Mar 21, 2024
P3, N=20, Not yet recruiting,  Sponsor: Amgen

|||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis. (Pubmed Central) - Mar 20, 2024
P2
Trial primary completion date: Jan 2024 --> Dec 2024 Erenumab is cost-effective versus topiramate as a preventive treatment for EM and versus placebo for patients with CM from the perspective of the Spanish National Health System.

|||||||||| Ibrance (palbociclib) / Pfizer
Journal: The CDK4/6 inhibitor Palbociclib synergizes with ATRA to induce differentiation in AML. (Pubmed Central) - Mar 20, 2024
These enhanced differentiation effects may be associated with the regulation of transcription factors, including RAR?, E2F1, and STAT1. Overall, our findings demonstrate that CDK4/6 inhibition sensitizes AML cells to ATRA and could guide the development of novel therapeutic strategies for AML patients.

|||||||||| ABP 938 (aflibercept biosimilar) / Amgen
Journal: Analytical and Functional Similarity of Aflibercept Biosimilar ABP (Pubmed Central) - Mar 20, 2024
Overall, our findings demonstrate that CDK4/6 inhibition sensitizes AML cells to ATRA and could guide the development of novel therapeutic strategies for AML patients. ABP

|||||||||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Journal, IO biomarker: Significance of Aneuploidy in Predicting Prognosis and Treatment Response of Uveal Melanoma. (Pubmed Central) - Mar 20, 2024
UM in this study was divided into three CNV subtypes, and a model based on eight aneuploidy score-related genes was established to evaluate the prognosis and drug treatment efficacy of UM patients. The current results may have the potential to help the clinical decision-making process for UM management.

|||||||||| Journal: Advances in targeted therapy for gastric cancer based on tumor driver genes. (Pubmed Central) - Mar 20, 2024
In addition, bemarituzumab targets overexpressed FGFR2, while zolbetuximab targets overexpressed CLDN18.2, significantly extending progression-free survival and overall survival in patients with gastric cancer in clinical trials. This article reviews the roles of tumor driver genes in the progression of gastric cancer; and the treatment strategies for gastric cancer based on targeting HER2, VEGF, FGFR2, CLDN18.2, MET and other tumor driver genes, aiming to provide reference for clinical application of targeted therapy for gastric cancer.

|||||||||| abiraterone acetate / Generic mfg.
Clinical, Journal, Metastases: Bone-Modifying Agents in Patients With High-Risk Metastatic Castration-Sensitive Prostate Cancer Treated With Abiraterone Acetate. (Pubmed Central) - Mar 19, 2024
The association between the use of bone-modifying agents (BMAs) and the outcomes among patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with abiraterone acetate plus prednisone (AAP) remains unclear...Use of BMAs was defined as the administration of bisphosphonates and denosumab within 90 days before and after randomization...Zoledronic acid was the most frequently administered BMA in both the AAP (93 [70.5%]) and the ADT (88 [67.2%]) cohorts...No evidence was found that the outcomes of BMA varied by AAP or ADT (hazard ratio for time to SRE, 0.99 [95% CI, 0.48-2.08]; P?=?.99 for interaction; hazard ratio for OS, 1.31 [95% CI, 0.88-1.96]; P?=?.18 for interaction). The findings of this cohort study suggest that use of BMAs was associated with a longer time to SRE in patients with high-risk mCSPC treated with ADT, with or without AAP, suggesting that BMA use might provide benefits to this population.

|||||||||| Enbrel (etanercept) / Pfizer, Amgen
Journal: Some Drugs Have Two Faces: Paradoxical Colitis in a Patient with Psoriatic Arthritis Previously Treated with Etanercept and IL-17 Inhibitors. (Pubmed Central) - Mar 19, 2024
She was later diagnosed with paradoxical indeterminate colitis that was masked and treated by subsequent biologics given for her RA and psoriatic arthritis. In this report, we will discuss the importance of considering paradoxical colitis in the differential diagnosis for patients even several years after TNF-?/IL-17 inhibitor initiation and explain why careful consideration must be made when initiating these colitis-inducing agents to treat patients with inflammatory disorders.

|||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Journal: Building a better blinatumomab. (Pubmed Central) - Mar 19, 2024
In this report, we will discuss the importance of considering paradoxical colitis in the differential diagnosis for patients even several years after TNF-?/IL-17 inhibitor initiation and explain why careful consideration must be made when initiating these colitis-inducing agents to treat patients with inflammatory disorders. No abstract available



	Diseases Companies Products Productz Mechanisms of Action Sites